跳到正文
ECA GMP News·精选AI 评分80

EMA 发布 Annex 15 修订概念文件,公开征求意见至 2026 年 4 月 9 日

Concept Paper Annex 15 Revision published

AI 导读

EMA 已发布 Annex 15 修订概念文件,并就该文件公开征求意见至 2026 年 4 月 9 日。概念文件将修订起因归于沙坦类药物中的亚硝胺杂质问题,沙坦案例管理经验报告建议对原料药生产商强制适用 Annex 15,而现行版本对原料药生产商仅为可选,修订还计划纳入 ICH Q9(R1) 质量风险管理的部分内容。

推荐理由

材料梳理了 Annex 15 修订因沙坦类亚硝胺问题启动的背景、拟对原料药生产商强制适用的变化及征求意见时间安排。

正文 · 原文

In the working plans of the European Medicines Agency (EMA) a new revision of Annex 15 was proposed in 2024. Now the concept paper for this revision has been published on EMA´s website. In the introduction it is described in detail that the N-nitrosamine impurities in sartan medicines triggered the revision of Annex 15. Why? The reasons were mentioned in the "Lesson learnt" report about the sartan case management: the lack of a sufficient process and product knowledge during the development stage and GMP deficiencies by active substance manufacturers - including inadequate investigation of quality issues and insufficient contamination control measures, among other points. Therefore the report recommends to make Annex 15 mandatory for active substance manufacturers in order to address the shortcomings identified and to ensure quality and safety of medicines. So a drafting group has initiated the update process. Additionally, it is planned to also implement parts of the updated ICH Q9 (R1) revision on quality risk management in the Annex 15 revision. The revised Annex 15 will be mandatory applicable to manufacturers of chemical and biological active substances. In the current version the use of Annex 15 is only optional for active substance manufacturers. And the timelines? There is a two month comment phase until 9th April 2026 planned for the concept paper. At the end of 2026 a final draft version schould be available. You find the whole concept paper on EMA´s website.

来源:ECA GMP News · gmp-compliance.org